Chad Ellis named UNC Lineberger Associate Director
Source Newsroom: University of North Carolina Health Care System
Newswise — In his new role at UNC Lineberger, Dr. Ellis will serve as the lead administrator for the center, overseeing the clinical protocol office, human resources, center finances, information technology as well as the physical infrastructure of the cancer center. Dr. Ellis will also play a critical role in updating the strategic plan that drives the University Cancer Research Fund, a $42 million state investment to support cancer research in North Carolina.
“We are thrilled to welcome Chad Ellis as the newest member of our senior leadership,” said Ned Sharpless, MD, director of UNC Lineberger. “This next year will be a tremendous time of growth for UNC Lineberger, and Chad’s experience and background are a perfect match to help us further sharpen our administrative, financial and research focus in the future.”
Prior to joining UNC Lineberger, Dr. Ellis served as the deputy director of research affairs at the Yale Comprehensive Cancer Center, where he led strategic planning activities for the center, oversaw cancer research activities, managed key infrastructure and administrative tasks, as well as handled faculty retention and recruitment. Ellis also completed his postdoctoral fellowship at the National Cancer Institute (NCI), where he focused on the regulation, activation and signaling pathways of Ras proteins and filed a patent application for the novel protein, Rig. After spending several years in industry and consulting, Ellis returned to NCI as a program director of the Cancer Centers Program. During that time, he oversaw a portfolio of 22 Comprehensive Cancer Support Grants awarded to NCI-designated cancer centers.
“I look forward to joining the amazing team at UNC Lineberger. Building upon my experience at Yale and NCI, I will work to help continue the tremendous growth accomplished by the center over the last several years,” said Ellis.
Dr. Ellis earned his bachelor’s degree in microbiology and cell science from the University of Florida and his PhD in pharmacology from the University of Illinois School of Medicine. He is also a two-time recipient of the highly selective NIH Fellows Award for Research Excellence and has been named as an NCI Outstanding Fellow.